Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
US FDA Rejects Outlook’s Lytenava for a Third Time, Citing Lack of Efficacy Evidence
Outlook Therapeutics reported Dec. 31 that the US FDA had issued a third complete response letter rejecting the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation...
US FDA Approves Ranibizumab (Lucentis) Biosimilar from Bioeq, Formycon
Swiss company Bioeq announced Dec. 23 that the US FDA had approved its ranibizumab (Lucentis) biosimilar for all the reference product’s indications: wet age-related neovascular macular degeneratio...
US FDA Accepts Viridian’s TED Candidate for Priority Review, Sets PDUFA Date of June 30, 2026
Viridian Therapeutics reported Dec. 22 that the US FDA had accepted its biologics license application (BLA) for veligrotug, the company’s intravenous treatment candidate for thyroid eye disease (TE...
Alvotech, Teva Reach Deal with Regeneron to Bring Eylea Biosimilar to US Market No Later than H2-2026
Alvotech and Teva reported Dec. 19 that they had reached a settlement and license agreement with Regeneron that clears the way for Teva to commercialize AVT06, a biosimilar to Eylea, in the US, if ...
CMS Issues Billing Codes for Cellution’s Allograft, Balance’s Pressure Goggles
The US Centers for Medicare and Medicaid Services (CMS) issued a Q-code in Q3-2025 for Cellution Biologics’ AmchoMatrixDL, an amnion membrane allograft that acts as a barrier and provides protectiv...
US FDA Gives Green Light to Trial of Viatris’ Gene Therapy Candidate for NK
Viatris reported on Dec. 18 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of MR-146, a gene therapy candi...
Virtual Retina Could Help Unlock New Treatments for Vision Loss, Researchers Say
New computer modeling could help scientists better understand how the retina regenerates, opening the door to new treatments for vision loss, researchers from the UK’s University of Surrey say. The...
USC Roski Eye Takes Part in Phase IIb Trial of RPE Patch Candidate for GA
Researchers at the University of Southern California Roski Eye Institute reported Dec. 17 that they are taking part in a Phase IIb trial of Regenerative Patch Technologies’ retinal pigmented epithe...
Meibum Scientific Appoints Ryan S. Bleeks as Interim CEO
Meibum Scientific, of Brentwood, Tennessee, announced Dec. 2 that it had appointed Ryan S. Bleeks as interim chief executive officer to lead the commercialization of dry eye treatment devices Bleph...
Evoq Launches Twilight Dark Adaptometer in US
Evoq Technologies announced Nov. 24 that its Twilight dark adaptometer is registered and listed with the FDA as a Class I medical device and is now available for sale in the US. The company website...
Formycon, Klinge License Eylea Biosimilar to NTC for Italy
German companies Formycon and Klinge Biopharma announced Nov. 24 that they had reached a deal with Italian pharmaceutical company NTC to license their Eylea (aflibercept) biosimilar for Italy. The ...
EssilorLuxottica Acquires Signifeye Eye Centers in Belgium
EssilorLuxottica reported Dec. 12 that it had acquired Signifeye, a network of 15 eye centers and clinics in the Flanders region of Belgium. The transaction is expected to close by Q1-2026. No fina...
Past News Stories
Argenx Pulls Plug on Thyroid Eye Disease Program on Recommendation of Data Monitors
Dutch drugmaker Argenx reported Dec. 15 that it would discontinue the Phase III program for subcutaneous efgartigimod in moderate to severe thyroid eye disease (TED). An independent data monitoring...
Health Canada Approves Celltrion’s Aflibercept Biosimilar Branded Eydenzelt
South Korea’s Celltrion announced Nov. 27 that Health Canada had approved Eydenzelt, an aflibercept (Eylea) biosimilar, in both vial and prefilled syringe formats. Eydenzelt (aflibercept-boav 40 mg...
Finland Researchers Study Heat’s Role in Slowing Progression of Dry AMD
Researchers at Aalto University in Finland announced Oct. 29 a promising approach to stopping the progression of dry age-related macular degeneration by using heat to trigger healing responses at t...
MIT Research Offers New Treatment Approach for Amblyopia
MIT researchers have demonstrated a new strategy for treating amblyopia in adults. The team showed that if the retina of the amblyopic eye is temporarily and reversibly anesthetized for a couple of...
Amneal Gains US FDA Approval for Generic Version of Restasis for Dry Eye
Amneal Pharmaceuticals announced Dec. 1 that it had received US FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. C...
Alembic Gains US FDA Approval for Generic of Bausch + Lomb’s Zylet
India’s Alembic Pharmaceuticals announced Dec. 11 that the US FDA had approved the abbreviated new drug application for its combination eye drop of loteprednol etabonate and tobramycin, referencing...
Kiora Joins RARE-X Consortium Promoting Collaboration on Rare Ocular Disorders
Kiora Pharmaceuticals announced Oct. 30 that it had joined Global Genes’ RARE-X Vision Consortium, aiming to promote collaboration among advocacy, research, and industry stakeholders to fight rare ...
Alcon Exercises Right to Again Delay STAAR Shareholders’ Vote on Deal
STAAR Surgical reported Dec. 19 that its shareholder vote on Alcon’s acquisition of the phakic IOL maker had been delayed until Jan. 6, due to Alcon exercising its right to push back the vote under...
Ocular Takes Cue from US FDA, Will Submit NDA for Axpaxli After Single Phase III Trial
Ocular Therapeutix announced Dec. 8 that it planned to submit a new drug application (NDA) to the US FDA for Axpaxli in wet age-related macular degeneration (AMD) if it sees positive one-year data ...
Carl Zeiss Meditec Reports Annual Ophthalmic Revenue of $2 Billion
Carl Zeiss Meditec reported Dec. 11 that ophthalmology revenue for the company’s full fiscal year 2024/2025, which ended Sept. 30, was €1.7 billion (US $2.0 billion, converted on Sept. 30, 2025), a...
Ophthalmologists Report 2.6 Percent Decrease in Q3-2025 Procedure Volume
US ophthalmologists reported that ophthalmic procedures decreased 2.6 percent in Q3-2025 compared with the same quarter in 2024, according to Market Scope’s latest survey. Year-over-year performanc...
US FDA Extends Action Date on Aldeyra’s Reproxalap to March 2026
Aldeyra Therapeutics reported Dec. 15 that the US FDA had extended the Prescription Drug User Fee Act (PDUFA) target action date for dry eye drop candidate reproxalap to March 16, 2026. The new dru...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.